2015
DOI: 10.1016/j.carres.2015.04.020
|View full text |Cite
|
Sign up to set email alerts
|

Development of new methods for determining the heparanase enzymatic activity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
14
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 18 publications
(14 citation statements)
references
References 43 publications
0
14
0
Order By: Relevance
“…20.1b) clinically used as antithrombotic agent [43]. As a good heparanase substrate, it has been included as a component of heparanase activity assay kit particularly useful for kinetic analysis and screening of enzyme inhibitors [44,45]. The heparanase cleavage site was described to be also dependent on the sulfation pattern of the neighboring sequences [46].…”
Section: Heparanase: Discovery and Characterizationmentioning
confidence: 99%
“…20.1b) clinically used as antithrombotic agent [43]. As a good heparanase substrate, it has been included as a component of heparanase activity assay kit particularly useful for kinetic analysis and screening of enzyme inhibitors [44,45]. The heparanase cleavage site was described to be also dependent on the sulfation pattern of the neighboring sequences [46].…”
Section: Heparanase: Discovery and Characterizationmentioning
confidence: 99%
“…Human endo‐β‐glucuronidases, such as heparanases, are responsible for the hydrolysis of β‐D‐glucuronic acid residues from the non‐reducing end of heparan sulfates (McCarter & Withers, ; Melo, Tersariol, Nader, Pinhal, & Lima, ). Heparanase expression is increased in glioma specimens in tumor and endothelial cells, and its expression has been correlated with proliferation, migration (Hong et al, ; Hong, Nelson, deCarvalho, & Kalkanis, ) and angiogenesis (Kundu et al, ; Zetser, Bashenko, Miao, Vlodavsky, & Ilan, ); as seen in other types of tumors (Cassinelli, Zaffaroni, & Lanzi, ; Crispel et al, ; Elkin et al, ; Vlodavsky, Elkin, & Ilan, ; Vornicova et al, ).…”
Section: Modulation Of Brain Extracellular Matrix By Proteases and Glmentioning
confidence: 99%
“…Recently, biotinylated HS was immobilised onto a protamine-coated plate. Following treatment with heparanase, the immobilised biotinylated HS not digested by heparanase was detected with a Eu-streptavidin conjugate [ 42 ]. Wu and coworkers [ 43 ] biotinylated HS at the non-reducing end in an elaborate but controlled fashion by first enzymatically attaching an azido-labelled sugar, GlcNAz, with the glycosyltransferase EXT1/2 to HS chains attached to the proteoglycan rhSynd4.…”
Section: Assaying Heparanasementioning
confidence: 99%
“…This assay is more rapid than the WST-1 method and is not affected by the presence of reducing sugars in the sample; however, it is unclear whether it can be adapted to biological samples because of the presence of multiple endogenous glycosaminoglycans (GAGs) in the latter. The second assay is a variation of the WST-1 assay and uses the sodium salt of resazurin [ 42 ], a commercially available dye which also reacts with reducing sugars. Unlike WST-1, the product of the reaction is fluorescent and is detected at 590 nm following excitation at 560 nm.…”
Section: Assaying Heparanasementioning
confidence: 99%